News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
BioSpace News Archive
Browse BioSpace’s published news and press releases by year, month, and day.
117 Results
Year
2005 (24679)
2006 (34770)
2007 (39687)
2008 (39410)
2009 (42118)
2010 (39616)
2011 (38383)
2012 (38416)
2013 (36268)
2014 (39673)
2015 (44433)
2016 (38330)
2017 (37191)
2018 (39124)
2019 (51338)
2020 (57666)
2021 (58724)
2022 (53928)
2023 (42568)
2024 (38486)
2025 (17535)
Month
January (2946)
February (2976)
March (2714)
April (2913)
May (3639)
June (2347)
Day
1 (8)
2 (81)
3 (24)
6 (132)
7 (216)
8 (201)
9 (223)
10 (129)
13 (236)
14 (204)
15 (97)
16 (109)
17 (66)
19 (3)
20 (31)
21 (142)
22 (117)
23 (165)
24 (70)
27 (156)
28 (137)
29 (116)
30 (191)
31 (92)
Year
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Month
January
February
March
April
May
June
Day
1
2
3
6
7
8
9
10
13
14
15
16
17
19
20
21
22
23
24
27
28
29
30
31
Deals
Almost 5 Years into $5B Galapagos Partnership, Gilead Execs Start Over With New Spinoff
Five years ago, Gilead signed a massive deal with Galapagos. After a restructuring, the pharma is still hunting for the potential it saw at the original signing.
January 22, 2025
·
5 min read
·
Annalee Armstrong
IPO
Chinese Biotech Ascentage Aims For $134M IPO
Ascentage is looking to use the IPO proceeds to advance its Phase III candidates for chronic or small lymphocytic leukemia and for certain types of chronic myeloid leukemia.
January 22, 2025
·
2 min read
·
Tristan Manalac
Regulatory
FDA Presses Pause on Atara’s Programs, Play on Amylyx’s ALS Assets
The FDA is putting Atara’s active Investigational New Drug applications on hold due to manufacturing concerns at a third-party provider while releasing Amylyx’s investigational ALS therapy from a previous pause.
January 22, 2025
·
2 min read
·
Tristan Manalac
Depression
J&J’s Spravato Makes Headway in Tough Depression Space With Monotherapy Approval
Spravato’s monotherapy nod on Tuesday comes after a series of setbacks in the depression space.
January 22, 2025
·
2 min read
·
Tristan Manalac
ADCs
ArriVent Joins Chinese Licensing Trend With Potential $1.2B+ ADC Deal with Lepu
With an eye toward advancing a novel antibody-drug conjugate for gastrointestinal cancers, ArriVent is the latest biopharma player to ink a deal with a Chinese biotech.
January 22, 2025
·
2 min read
·
Tristan Manalac
Business
Trump Takes Over, Wegovy Still Trails Zepbound and
BioSpace
Recaps JPM
Biopharma executives shared their thoughts on the potential impacts of the new administration; Annalee Armstrong recaps JPM and her talks with Biogen, Gilead, Novavax and more; Wegovy’s higher dose induces more weight loss; AstraZeneca and Daiichi Sankyo’s Dato-DXd scores its first FDA approval.
January 22, 2025
·
1 min read
·
Heather McKenzie
Government
WHO Withdrawal, CGT Access, IRA: Trump’s Initial Policies Raise Questions for Biopharma
At J.P. Morgan, most biopharma executives expressed a neutral stance on the incoming administration, but just days later, President Trump issued multiple executive orders that concern the industry.
January 22, 2025
·
5 min read
·
Annalee Armstrong
Earnings
J&J Says Deals Likely to Shrink After $14.6B Intra-Cellular Buy
On the company’s Q4 earnings call where an eyepopping $88.8 billion in full-year sales were revealed, leaders shifted focus away from enormous takeovers to single-digit billion buy outs.
January 22, 2025
·
3 min read
·
Annalee Armstrong
Pain
Tris Pharma Records Late-Stage Win for Non-Opioid Painkiller
Cebranopadol, a dual-NMR agonist, reached the primary endpoint in a Phase III trial and matched placebo for safety, a significant concern in the analgesic field.
January 22, 2025
·
1 min read
·
Dan Samorodnitsky
Press Releases
Myriad Genetics Announces Hereditary Cancer Risk Assessment Program Study Published in Obstetrics & Gynecology
January 22, 2025
·
4 min read
1 of 12
Next